secwatch / observer

8-K filed June 1, 2026, 4:01 PM ET ticker ORKA CIK 0000907654

other material confidence high sentiment positive materiality 0.60

Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030

Oruka Therapeutics, Inc.

Oruka amended IL-23 license with Paragon to expand field to include inflammatory bowel disease (IBD).
Cannot dose ORKA-001 in combination IBD trial before June 1, 2028, or monotherapy before June 1, 2030.
If material transaction occurs (e.g., change of control), monotherapy restriction ends June 1, 2028.
Paragon's exclusivity for monospecific antibodies in IBD extended to October 11, 2029.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-26-063481
form_type: 8-K
ticker: ORKA
cik: 0000907654
company_name: Oruka Therapeutics, Inc.
filed_at: 2026-06-01T20:01:27+00:00
discovered_at: 2026-06-01T20:04:03.586952+00:00
generated_at: 2026-06-01T20:04:53.115064+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-26-063481
json_url: https://secwatch.observer/filing/0001213900-26-063481.json
markdown_url: https://secwatch.observer/filing/0001213900-26-063481.md
text_url: https://secwatch.observer/filing/0001213900-26-063481.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/0001213900-26-063481-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/ea0292876-8k_oruka.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

EMYB

Embassy Bancorp expands stock repurchase program by additional $5M

Embassy Bancorp, Inc. June 1, 2026, 4:37 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

XAIR

Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026

Beyond Air, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTXR

Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned

Citius Pharmaceuticals, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTOR

Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

CITIUS ONCOLOGY, INC. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

SYRE

Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

Spyre Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends

Via Renewables, Inc. June 1, 2026, 3:06 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

BUKS

CEO Christopher Reedy discloses ongoing cancer treatment; remains in role

BUTLER NATIONAL CORP June 1, 2026, 12:41 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CPSH

CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share

CPS TECHNOLOGIES CORP/DE/ June 1, 2026, 9:35 AM ET other_material Items 1.01, 5.03, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001213900-26-063481

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.